Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Chemed Corporation stock logo
CHE
Chemed
$534.93
-0.1%
$496.79
$365.20
$557.00
$7.00B0.51168,375 shs115,466 shs
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$31.95
+2.8%
$32.23
$13.74
$65.30
$7.25B2.415.91 million shs18.88 million shs
Hinge Health Inc. stock logo
HNGE
Hinge Health
$85.66
-3.2%
$80.94
$30.08
$93.13
$7.14B1.31.66 million shs1.40 million shs
Progyny, Inc. stock logo
PGNY
Progyny
$25.96
+1.7%
$29.15
$16.10
$33.06
$1.96B1.011.15 million shs1.14 million shs
7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Chemed Corporation stock logo
CHE
Chemed
-0.17%-0.27%+6.13%+21.66%+17.31%
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
+2.97%+10.96%-2.57%+34.75%-26.51%
Hinge Health Inc. stock logo
HNGE
Hinge Health
-3.17%-2.13%+1.64%+55.47%+49.52%
Progyny, Inc. stock logo
PGNY
Progyny
+1.68%+0.27%-19.48%+4.34%+15.07%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Chemed Corporation stock logo
CHE
Chemed
$534.93
-0.1%
$496.79
$365.20
$557.00
$7.00B0.51168,375 shs115,466 shs
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$31.95
+2.8%
$32.23
$13.74
$65.30
$7.25B2.415.91 million shs18.88 million shs
Hinge Health Inc. stock logo
HNGE
Hinge Health
$85.66
-3.2%
$80.94
$30.08
$93.13
$7.14B1.31.66 million shs1.40 million shs
Progyny, Inc. stock logo
PGNY
Progyny
$25.96
+1.7%
$29.15
$16.10
$33.06
$1.96B1.011.15 million shs1.14 million shs
7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Chemed Corporation stock logo
CHE
Chemed
-0.17%-0.27%+6.13%+21.66%+17.31%
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
+2.97%+10.96%-2.57%+34.75%-26.51%
Hinge Health Inc. stock logo
HNGE
Hinge Health
-3.17%-2.13%+1.64%+55.47%+49.52%
Progyny, Inc. stock logo
PGNY
Progyny
+1.68%+0.27%-19.48%+4.34%+15.07%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Chemed Corporation stock logo
CHE
Chemed
2.17
Hold$530.75-0.78% Downside
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
2.19
Hold$32.431.51% Upside
Hinge Health Inc. stock logo
HNGE
Hinge Health
2.83
Moderate Buy$100.5717.41% Upside
Progyny, Inc. stock logo
PGNY
Progyny
2.85
Moderate Buy$34.3632.37% Upside

Current Analyst Ratings Breakdown

Latest PGNY, HNGE, CHE, and HIMS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/20/2026
Progyny, Inc. stock logo
PGNY
Progyny
Initiated CoverageOverweight$37.00
8/13/2026
Progyny, Inc. stock logo
PGNY
Progyny
UpgradeHold (C)Hold (C+)
8/13/2026
Progyny, Inc. stock logo
PGNY
Progyny
Boost Price TargetBuy$33.00 ➝ $36.00
8/12/2026
Progyny, Inc. stock logo
PGNY
Progyny
Lower Price TargetEqual Weight$34.00 ➝ $30.00
8/11/2026
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Boost Price TargetHold$25.00 ➝ $26.00
8/11/2026
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Boost Price TargetHold$25.00 ➝ $30.00
8/11/2026
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Boost Price TargetEqual Weight$21.00 ➝ $28.00
8/11/2026
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Lower Price TargetNeutral$35.00 ➝ $33.00
8/11/2026
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Boost Price TargetNeutral$30.00 ➝ $32.00
8/11/2026
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Boost Price TargetBuy$35.00 ➝ $42.00
8/11/2026
Hinge Health Inc. stock logo
HNGE
Hinge Health
DowngradeStrong-BuyHold
(Data available from 8/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Chemed Corporation stock logo
CHE
Chemed
$2.53B2.76$24.63 per share21.72$63.54 per share8.42
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$2.35B3.18$0.86 per share37.15$1.39 per share22.99
Hinge Health Inc. stock logo
HNGE
Hinge Health
$720.06M9.60N/AN/A$4.27 per share20.06
Progyny, Inc. stock logo
PGNY
Progyny
$1.31B1.52$0.75 per share34.68$5.91 per share4.39
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Chemed Corporation stock logo
CHE
Chemed
$265.24M$19.9126.8721.022.0310.60%31.77%18.90%10/27/2026 (Estimated)
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$128.37M-$0.63N/A63.90N/A-5.51%-6.51%-1.20%11/9/2026 (Estimated)
Hinge Health Inc. stock logo
HNGE
Hinge Health
-$528.26M$1.2866.9262.99N/A15.15%51.60%14.16%N/A
Progyny, Inc. stock logo
PGNY
Progyny
$58.52M$0.9228.2218.951.856.00%15.98%10.65%11/5/2026 (Estimated)

Latest PGNY, HNGE, CHE, and HIMS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/10/2026Q2 2026
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
-$0.0498-$0.37-$0.3202-$0.37$698.90 million$753.21 million
8/6/2026Q2 2026
Progyny, Inc. stock logo
PGNY
Progyny
$0.3348$0.55+$0.2152$0.34$349.05 million$350.51 million
8/4/2026Q2 2026
Hinge Health Inc. stock logo
HNGE
Hinge Health
$0.28$0.59+$0.31$0.52N/A$212.82 million
7/28/2026Q2 2026
Chemed Corporation stock logo
CHE
Chemed
$5.60$6.06+$0.46$5.13$665.04 million$673.25 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Chemed Corporation stock logo
CHE
Chemed
$2.800.52%+10.76%14.06%16 Years
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
N/AN/AN/AN/AN/A
Hinge Health Inc. stock logo
HNGE
Hinge Health
N/AN/AN/AN/AN/A
Progyny, Inc. stock logo
PGNY
Progyny
N/AN/AN/AN/AN/A

Latest PGNY, HNGE, CHE, and HIMS Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/6/2026
Chemed Corporation stock logo
CHE
Chemed
quarterly$0.700.53%8/17/20268/17/20269/3/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Chemed Corporation stock logo
CHE
Chemed
0.17
0.91
0.89
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
4.21
0.93
0.87
Hinge Health Inc. stock logo
HNGE
Hinge Health
N/A
1.34
1.30
Progyny, Inc. stock logo
PGNY
Progyny
N/A
2.14
2.14

Institutional Ownership

CompanyInstitutional Ownership
Chemed Corporation stock logo
CHE
Chemed
95.85%
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
63.52%
Hinge Health Inc. stock logo
HNGE
Hinge Health
N/A
Progyny, Inc. stock logo
PGNY
Progyny
94.93%

Insider Ownership

CompanyInsider Ownership
Chemed Corporation stock logo
CHE
Chemed
3.33%
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
11.76%
Hinge Health Inc. stock logo
HNGE
Hinge Health
18.92%
Progyny, Inc. stock logo
PGNY
Progyny
9.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Chemed Corporation stock logo
CHE
Chemed
15,81113.07 million12.64 millionOptionable
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
2,442233.31 million205.88 millionOptionable
Hinge Health Inc. stock logo
HNGE
Hinge Health
1,43780.69 million65.43 millionN/A
Progyny, Inc. stock logo
PGNY
Progyny
31076.73 million69.13 millionOptionable

Recent News About These Companies

Bank of America Corp DE Grows Stake in Progyny, Inc. $PGNY
Progyny (PGNY) Q2 2026 Earnings Call Transcript
Progyny Q2 Earnings Call Highlights
Progyny, Inc. (PGNY) Q2 2026 Earnings Call Transcript
Progyny, Inc. Announces Second Quarter 2026 Results

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Chemed stock logo

Chemed NYSE:CHE

$534.93 -0.77 (-0.14%)
Closing price 08/20/2026 03:58 PM Eastern
Extended Trading
$534.78 -0.15 (-0.03%)
As of 08/20/2026 05:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees. The company was incorporated in 1970 and is headquartered in Cincinnati, Ohio.

Hims & Hers Health stock logo

Hims & Hers Health NYSE:HIMS

$31.95 +0.86 (+2.77%)
Closing price 08/20/2026 03:58 PM Eastern
Extended Trading
$31.88 -0.07 (-0.21%)
As of 08/20/2026 06:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hinge Health stock logo

Hinge Health NYSE:HNGE

$85.66 -2.80 (-3.17%)
Closing price 08/20/2026 03:58 PM Eastern
Extended Trading
$85.90 +0.24 (+0.28%)
As of 08/20/2026 06:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Our vision is to build a new health system that transforms outcomes, experience and costs by using technology to scale and automate the delivery of care. Hinge Health leverages software, including AI, to largely automate care for joint and muscle health, delivering an outstanding member experience, improved member outcomes, and cost reductions for our clients. We have designed our platform to address a broad spectrum of MSK care—from acute injury, to chronic pain, to post-surgical rehabilitation. Members receive personalized and largely automated MSK care through our AI-powered motion tracking technology and a proprietary electrical nerve stimulation wearable device, all designed and monitored by our AI-supported care team of licensed physical therapists, physicians, and board-certified health coaches. Our platform can improve pain and function and reduce the need for surgeries, all while driving health equity by allowing members to engage in their exercise therapy sessions from anywhere and embrace movement as a way of life. There is no shortage of new technologies in the healthcare industry, yet the cost of care continues to rise. In other industries, the launch of new technologies has generally improved end-user experiences and lowered costs. In healthcare, however, new technologies have not always been successful in lowering the cost of care or improving clinical outcomes. We believe there are two key reasons for healthcare’s idiosyncratic response to technology: • Automating most aspects of care is difficult because so many healthcare interventions involve unstructured physical tasks. • The current framework for healthcare reimbursement has specific pathways to pay for care, which means new technologies are constrained to deliver within this framework. At Hinge Health, we have taken these challenges head-on. To address the automation of care, we have weaved together AI-enabled capabilities - such as our AI-powered motion tracking technology, TrueMotion, our proprietary FDA-cleared wearable device, Enso, and our AI-supported care team - to deliver scalable and personalized MSK care. According to our estimates based on data from 2024, our platform reduced the number of human care team hours associated with traditional physical therapy by approximately 95%. We have done this while improving our high member satisfaction over time. To address healthcare reimbursement constraints, we developed novel billing methods for our innovative technology by both directly selling to employers while also partnering with health plans, pharmacy benefit managers (“PBMs”), third-party administrators (“TPAs”), and other ecosystem entities to efficiently provide our platform to clients and members. While the MSK market is massive, existing solutions have fallen short as they are often expensive, ineffective, inconvenient to access, and delivered in a one-to-one or few-to-one care setting. Effective MSK care should be engaging, easy to use, and accessible anytime, anywhere. We developed Hinge Health to be simple and accessible, complete, personalized, and scalable. • Simple and accessible: We provide members access to our platform at no direct cost to them and without a copay or deductible. Members can access our broad spectrum of MSK care through a single on-demand app, designed to provide an engaging, seamless, and convenient digital experience whenever and wherever the member chooses. Potential members can complete a simple intake form, download the app, and start exercises soon thereafter. During the year ended December 31, 2024, approximately 64% of members were onboarded on the same day they completed their intake form, and approximately 75% of members were onboarded within the first week. • Complete: Our platform offers a wide range of support with multiple programs across many affected areas to provide a continuum of care from prevention to treatment of acute injury and chronic pain, as well as surgery decision support and post-surgical recovery. We also offer non-addictive and non-invasive pain relief via electrostimulation through our proprietary FDA-cleared wearable device, Enso, that is seamlessly integrated into our platform. • Personalized: Our platform delivers smarter care through AI and machine learning. Our AI model is trained on a large, proprietary MSK data set, and our technology is continuously learning and improving as each new member enrolls and engages with our programs, which creates a positive feedback loop. As of March 31, 2025, we had treated over one million members and our programs had tracked over 74 million activity sessions and 32 million member-reported outcome logs. We focus on personalization to keep members moving: from customized care plans to real-time in-app exercise feedback based on the member’s input and our proprietary motion tracking technology. • Scalable: Our AI-powered motion tracking technology, TrueMotion, allows us to deliver scalable and largely automated care. According to our estimates based on data from 2024, our platform reduced the number of human care team hours associated with traditional physical therapy by approximately 95%. While most of our programs provide members with access to a dedicated care team, our technology automates most aspects of care delivery while allowing our members to progress through their exercise therapy sessions on their own time. We have developed an efficient go-to-market model by working directly with our partners and clients. We seek to be the best solution on the market, the most validated solution on the market, and the easiest to buy. Our clients are primarily self-insured employers and include many of the nation’s leading enterprises across a broad range of industries and sizes. Within this segment, we also serve many public sector self-insured employers, such as state and local city governments and labor unions. In most instances, we partner with clients’ health plans, TPAs, PBMs, or other ecosystem entities to reduce the friction of contracting, procurement, security and IT reviews, onboarding, and billing. We are also in the early stages of expanding to serve health plans’ fully-insured and Medicare Advantage populations and federal insurance plans. As of December 31, 2024, we had approximately 20 million contracted lives across more than 2,250 clients. We had active client agreements with 49% of the Fortune 100 companies and 42% of the Fortune 500 companies, as of December 31, 2024. Despite this progress, our current contracted lives only represent 5% of our total addressable market. We believe that we grow efficiently because of our scalable, repeatable go-to-market model. We sell through our direct sales force and our partners. Once we contract with a client, we are most often the sole digital MSK care provider offered to their contracted lives. Our average contract term is three years. For the term of each contract, we are able to enroll, engage, and re-engage the client’s eligible lives, driving a recurring, repeatable revenue model, which is demonstrated in our net dollar retention of 117% as of December 31, 2024. Our 12-month client retention rate was 98% as of December 31, 2024. Additionally, we have a high level of client satisfaction, as shown by our client net promoter score (“NPS”) of 87 as of October 31, 2024. We also invested early in building our partner network. As of March 31, 2025, we had over 50 partners. Our partners include the five largest national health plans by self-insured lives, and the top three PBMs by market share. As of that date, we had retained 100% of our partners that we chose to work with since inception, excluding partners who were acquired. We have experienced significant growth since our inception, with a recurring revenue business model. As of December 31, 2024, we had over 532,000 members and more than 2,250 clients, compared to approximately 371,000 members and approximately 1,650 clients as of December 31, 2023. Our principal executive offices are located in San Francisco, California.

Progyny stock logo

Progyny NASDAQ:PGNY

$25.96 +0.43 (+1.68%)
Closing price 08/20/2026 04:00 PM Eastern
Extended Trading
$26.30 +0.34 (+1.31%)
As of 08/20/2026 06:03 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides assistance service programs where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.